Retatrutide TRIUMPH-1 Phase 3 Results: 30% Weight Loss Achieved

The Most Powerful Weight Loss Drug Ever Tested

In May 2026, Eli Lilly announced topline results from TRIUMPH-1, the pivotal Phase 3 trial for retatrutide. The numbers exceeded even optimistic predictions:

• 12mg dose: 28.3% body weight loss at 80 weeks (avg 70.3 lbs)
• 9mg dose: 25.9% loss at 80 weeks (avg 64.4 lbs)
• 4mg dose: 19.0% loss at 80 weeks (avg 47.2 lbs)
• Placebo: 2.2% loss

For participants with severe obesity (BMI ≥35) who continued to 104 weeks on the 12mg dose, average loss reached 30.3% — approximately 85 lbs.

How It Compares

Drug	Max Weight Loss	Timeline
Retatrutide 12mg	28-30%	80-104 weeks
Tirzepatide 15mg	20-22%	72 weeks
Semaglutide 2.4mg	15-17%	68 weeks
Liraglutide 3.0mg	8-9%	56 weeks

Retatrutide's advantage is substantial — roughly 10 percentage points more than tirzepatide, the current most effective approved drug.

The Triple Mechanism

Retatrutide activates three receptors simultaneously:

1. GLP-1 — suppresses appetite, slows gastric emptying (same as Ozempic/Wegovy)
2. GIP — improves insulin sensitivity, may support bone density (same addition as Mounjaro)
3. Glucagon — increases energy expenditure, promotes fat oxidation, reduces liver fat

The glucagon component is what sets retatrutide apart. While GLP-1 and GIP reduce intake, glucagon actively increases metabolic rate — you burn more calories even at rest.

Side Effects in TRIUMPH-1

GI side effects were consistent with the drug class but manageable:

• Nausea: reported in 22% (mostly mild-moderate, during titration)
• Diarrhea: 16%
• Constipation: 12%
• Vomiting: 10%

Discontinuation due to side effects was low (~6%), suggesting the titration protocol effectively managed tolerability.

What Happens Next

• Additional TRIUMPH trials are ongoing (diabetes, MASH/liver disease, cardiovascular outcomes)
• FDA submission expected late 2026 or early 2027
• If approved, brand name and pricing are not yet announced
• Estimated availability: 2027-2028

Bottom Line

TRIUMPH-1 establishes retatrutide as the most effective anti-obesity medication ever tested in a large clinical trial. For people who have plateaued on semaglutide or tirzepatide, retatrutide may eventually offer a next-level option — though it remains 1-2 years from market availability.